Treatment-Related Deaths and Second Cancer Risk After

Treatment-Related Deaths and Second Cancer Risk After
Autologous Stem-Cell Transplantation for Hodgkin’s
Disease
by Marc André, Michel Henry-Amar, Didier Blaise, Philippe Colombat, Joël Fleury,
Noël Milpied, Jean-Yves Cahn, José-Luis Pico, Yves Bastion, Mathieu Kuentz,
Gérard Nedellec, Michel Attal, Christophe Fermé, and Christian Gisselbrecht
Blood
Volume 92(6):1933-1940
September 15, 1998
©1998 by American Society of Hematology

Cumulative incidence of all second cancers (SC), myelodysplasia/acute myeloid leukemia
(MDS/AML) and solid tumors (ST) after ASCT in 467 HD patients (PSD, PRD, R1, and R2 groups)
with a median follow up of 21 months since ASCT.
Marc André et al. Blood 1998;92:1933-1940
©1998 by American Society of Hematology

Cumulative incidence of second malignancies in the matched 393 grafted and 1179
conventionally treated HD patients (PSD, PRD, R1) since ASCT or last treatment.
Marc André et al. Blood 1998;92:1933-1940
©1998 by American Society of Hematology